Show simple item record

dc.contributor.authorKramp, KL
dc.contributor.authorDeWitt, K
dc.contributor.authorFlora, JW
dc.contributor.authorMuddiman, DC
dc.contributor.authorSlunt, KM
dc.contributor.authorHouston, TA
dc.date.accessioned2017-05-03T13:55:49Z
dc.date.available2017-05-03T13:55:49Z
dc.date.issued2005
dc.identifier.issn0040-4039
dc.identifier.doi10.1016/j.tetlet.2004.11.112
dc.identifier.urihttp://hdl.handle.net/10072/4947
dc.description.abstractThe Leishmania lipophosphoglycan (LPG) is the most abundant cell surface glycoconjugate of a family of infectious protozoa. Pentamidine, a common drug used in the treatment of Leishmania infections, has been modified with boronic acids so that it might bind more selectively to the phosphodisaccharide repeating unit of the LPG. This could serve to target the drug to the protozoan surface and increase its efficacy in vivo
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier - Pergamon
dc.publisher.placeOxford, UK
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom695
dc.relation.ispartofpageto698
dc.relation.ispartofjournalTetrahedron Letters
dc.relation.ispartofvolume46
dc.rights.retentionY
dc.subject.fieldofresearchMedicinal and biomolecular chemistry
dc.subject.fieldofresearchOrganic chemistry
dc.subject.fieldofresearchcode3404
dc.subject.fieldofresearchcode3405
dc.titleDerivatives of pentamidine designed to target the Leishmania lipophosphoglycan
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.date.issued2015-05-11T00:49:20Z
gro.hasfulltextNo Full Text
gro.griffith.authorHouston, Todd A.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record